Osiris Therapeutics (OSIR) Wins Second Approval for Prochymal

Article Stock Quotes (1) Comments (0)

Osiris Therapeutics, Inc. (NASDAQ: OSIR), announced today it has received consent from New Zealand to market its first-in-class stem cell therapy Prochymal® (remestemcel-L), for the treatment of acute graft-vs-host disease (GvHD) in children. With this decision New Zealand joins Canada, which last month became the world’s first internationally recognized regulatory authority to grant approval to a stem cell drug. Prochymal is also the first therapy approved for GvHD - a devastating complication of bone marrow transplantation that kills up to 80 percent of children affected, many within just weeks of diagnosis.

---

Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW

---

*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here

---

---

You May Also Be Interested In

• Cytokinetics (CYTK) ATOMIC-AHF Results to Be Presented at ESC Congress 2013 (AMGN)
• Genetic Tech (GENE) Updates on Impact of SCOTUS Ruling on Gene Patenting
• GlaxoSmithKline (GSK) Receives Bid for Thrombosis Brands, NDB Site

Create E-mail Alert Related Categories

Corporate News, FDA

Add Your Comment

Name

Subject

Body

Share on Facebook

Verification
can't see the text?
click here to refresh the image.
what's this?